Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 04:00PM ET
2.38
Dollar change
+0.03
Percentage change
1.28
%
IndexRUT P/E- EPS (ttm)-1.70 Insider Own40.74% Shs Outstand149.33M Perf Week20.20%
Market Cap359.59M Forward P/E- EPS next Y-1.04 Insider Trans3.43% Shs Float89.54M Perf Month37.57%
Income-230.59M PEG- EPS next Q-0.21 Inst Own37.35% Short Float11.47% Perf Quarter19.90%
Sales0.00M P/S- EPS this Y54.41% Inst Trans3.21% Short Ratio8.00 Perf Half Y-7.57%
Book/sh2.25 P/B1.06 EPS next Y-14.35% ROA-53.26% Short Interest10.27M Perf Year-33.89%
Cash/sh1.96 P/C1.21 EPS next 5Y- ROE-65.48% 52W Range1.51 - 3.70 Perf YTD11.74%
Dividend Est.- P/FCF- EPS past 5Y- ROI-58.84% 52W High-35.72% Beta1.14
Dividend TTM- Quick Ratio11.45 Sales past 5Y0.00% Gross Margin- 52W Low57.62% ATR (14)0.18
Dividend Ex-Date- Current Ratio11.45 EPS Y/Y TTM-47.29% Oper. Margin0.00% RSI (14)67.24 Volatility13.90% 8.03%
Employees129 Debt/Eq0.17 Sales Y/Y TTM- Profit Margin- Recom1.29 Target Price6.83
Option/ShortYes / Yes LT Debt/Eq0.16 EPS Q/Q31.31% Payout- Rel Volume2.01 Prev Close2.35
Sales Surprise- EPS Surprise13.01% Sales Q/Q- EarningsNov 09 AMC Avg Volume1.28M Price2.38
SMA2024.41% SMA5023.33% SMA2002.00% Trades Volume2,571,236 Change1.28%
Date Action Analyst Rating Change Price Target Change
Jan-05-24Downgrade BofA Securities Buy → Neutral $11 → $6
Oct-11-23Initiated H.C. Wainwright Buy $10
Mar-30-23Initiated Mizuho Buy $9
Feb-24-23Initiated Goldman Buy $10
Feb-03-23Upgrade Morgan Stanley Equal-Weight → Overweight $15
Feb-14-24 08:00AM
Feb-01-24 08:00AM
Jan-03-24 08:00AM
Dec-20-23 01:34PM
Dec-11-23 08:00AM
08:00AM Loading…
Nov-28-23 08:00AM
Nov-09-23 04:01PM
Nov-08-23 08:00AM
Oct-12-23 11:28AM
Oct-10-23 03:56PM
Sep-19-23 08:00AM
Sep-05-23 08:00AM
Aug-29-23 08:00AM
Aug-10-23 04:01PM
Jul-12-23 06:35AM
04:01PM Loading…
Jun-22-23 04:01PM
Jun-15-23 06:22AM
Jun-06-23 10:53AM
Jun-05-23 04:01PM
Jun-01-23 08:00AM
May-31-23 08:00AM
May-25-23 05:00PM
09:01AM
May-16-23 08:00AM
May-15-23 04:01PM
May-02-23 08:00AM
May-01-23 08:00AM
Apr-26-23 05:00PM
Apr-25-23 08:00AM
Apr-18-23 09:00AM
07:07AM Loading…
Apr-12-23 07:07AM
Apr-10-23 08:00AM
Mar-31-23 06:19AM
Mar-30-23 04:21AM
Mar-23-23 04:01PM
Mar-14-23 04:31PM
Feb-01-23 08:00AM
Jan-16-23 06:19AM
Jan-11-23 03:04PM
Jan-04-23 08:00AM
Dec-20-22 08:00AM
Dec-17-22 07:28AM
Dec-16-22 07:15AM
Dec-13-22 08:00AM
Dec-09-22 10:00AM
07:34AM
07:32AM
Nov-30-22 08:00AM
Nov-22-22 08:00AM
Nov-14-22 09:55AM
Nov-09-22 04:01PM
Oct-20-22 08:00AM
Oct-12-22 08:00AM
Sep-26-22 08:00AM
Sep-09-22 08:31AM
Sep-08-22 11:08AM
Sep-07-22 04:05PM
Aug-24-22 08:00AM
Aug-23-22 09:55AM
08:00AM
Aug-19-22 09:55AM
Aug-11-22 04:05PM
Aug-08-22 09:29AM
Aug-03-22 09:55AM
Jul-27-22 06:00PM
Jul-21-22 06:00PM
Jul-18-22 06:15PM
09:55AM
08:00AM
Jul-12-22 06:00PM
Jul-06-22 06:15PM
Jun-09-22 09:55AM
Jun-03-22 09:00AM
Jun-02-22 08:00AM
May-25-22 08:00AM
May-23-22 09:55AM
May-12-22 04:01PM
May-03-22 08:00AM
Apr-27-22 08:00AM
Apr-15-22 07:42AM
Apr-12-22 04:01PM
Apr-06-22 08:00AM
Mar-24-22 04:05PM
Mar-10-22 08:00AM
Mar-08-22 04:31PM
Mar-01-22 04:14PM
Feb-08-22 09:04AM
Feb-03-22 08:00AM
Jan-27-22 01:38PM
Jan-18-22 08:00AM
Jan-04-22 08:00AM
Dec-24-21 12:38AM
Dec-18-21 12:38AM
Dec-17-21 08:00AM
Dec-16-21 09:38AM
Dec-15-21 05:46AM
Dec-14-21 08:00AM
Dec-11-21 05:38AM
Nov-16-21 08:00AM
Nov-10-21 04:05PM
Erasca, Inc. is a clinical stage precision oncology company, It focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lim Jonathan EChairman & CEODec 06Buy1.72278,150478,41812,899,360Dec 06 07:41 PM
Start Valerie Denise HardingDirectorDec 06Buy1.8510,00018,48020,000Dec 08 09:10 AM
Lim Jonathan EChairman & CEODec 05Buy1.69721,8501,217,76112,899,360Dec 06 07:41 PM
Casdin Alexander W.DirectorDec 04Buy1.6630,00049,785493,974Dec 04 06:23 PM
Lim Jonathan EChairman & CEOOct 05Buy2.031,000,0002,026,00019,456,216Oct 10 08:00 AM
Lim Jonathan EChairman & CEOJun 08Buy2.75100,000275,00018,396,216Jun 08 08:54 PM
Casdin Alexander W.DirectorApr 10Buy2.7620,00055,230463,974Apr 11 08:23 AM
Lim Jonathan EChairman & CEOMar 28Buy2.84100,000284,00018,296,216Mar 28 09:24 PM